Jaguar Health (NASDAQ: JAGX)
@Jaguar_Health
Followers
3,447
Following
261
Media
302
Statuses
580
We develop novel plant-based, sustainably derived Rx drugs for people & animals with GI distress. | Social Media Policy:
San Francisco, CA
Joined March 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
taeil
• 1317634 Tweets
#湊あくあ卒業ライブ
• 873772 Tweets
Arlington
• 409529 Tweets
ホロライブ
• 214029 Tweets
伝説のアイドル
• 77366 Tweets
Marley
• 37096 Tweets
$NVDA
• 33260 Tweets
西鉄バス
• 31230 Tweets
OpenSea
• 27609 Tweets
あくたん6年間
• 26519 Tweets
ドーピング
• 23712 Tweets
カグラバチ
• 21421 Tweets
#العمق_فيصل_هدلان
• 15469 Tweets
月見パイ
• 14133 Tweets
Araceli Saucedo
• 13326 Tweets
Salzburg
• 12721 Tweets
朝倉未来
• 12458 Tweets
ふつうの軽音部
• 11757 Tweets
DONBELLE NEW PROJECT
• 11574 Tweets
SMCI
• 10694 Tweets
Muniain
• 10591 Tweets
Jaguar Health announced the activation of the investigational new drug (IND) application filed by its subsidiary
@NapoPharma
for use of Napo’s plant-based medicine for prophylaxis & symptomatic relief of cancer therapy-related diarrhea
#PlantBasedMedicines
3
15
54
Foal medicine specialist, Dr. Siobhan McAuliffe, presents a general overview of diarrhea in foals.
#FoalHealth
2
17
47
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
#JAGX
0
8
38
Jaguar Health today announced that it has established a new Investigational New Animal Drug file with the Center for Veterinary Medicine of the U.S. Food and Drug Administration for crofelemer to treat general, non-infectious diarrhea in dogs.
0
4
34
Jaguar Health Announces Submission of Clinical Trial Applications for the Rare Disease Indications Microvillus Inclusion Disease and Short Bowel Syndrome in Europe
#JAGX
0
8
33
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
#JAGX
0
6
33
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
#JAGX
0
7
31
Save the date: On August 13 at 8:30 am ET Jaguar Health will host an investor call to review second-quarter 2020 financials and business updates for $JAGX. Get details here:
#PlantBasedMedicines
0
8
28
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
#JAGX
0
4
28
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
#JAGX
0
2
28
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
#JAGX
0
5
27
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
0
4
27
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance.
0
8
23
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and 8 Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
0
4
24
Today on
#WorldAIDSDay
, we reflect on the worldwide response to the HIV/AIDS epidemic, while also remembering those we've lost. This year’s theme of “Resilience and Impact” is more important than ever & we are proud to be part of such an inspiring community.
#PlantBasedMedicines
11
2
22
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
#JAGX
0
4
22
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Cholera-Related Diarrhea
0
7
20
Jaguar Health to present January 31 at The Microcap Conference and participate in a fireside chat February 1 at the Lytham Partners Investor Select Conference
0
6
20
Jaguar Health subsidiary
@NapoPharma
announced today the initiation of a 28-day preclinical toxicology and safety study to support development of our
#plantbased
drug candidate for
#cholera
. Read more:
#PlantBasedMedicines
2
7
19
Jaguar today announced that it has reached agreement with the FDA on the design and conduct of a clinical field study of Canalevia-CA1, the company's FDA conditionally approved prescription drug for dogs, for full approval of the product.
0
3
20
Jaguar Health Reports Q1 2024 Financial Results; Investor Webcast 8:30 a.m. Eastern Today
#JAGX
0
3
20
Today Jaguar Health provided 2020 third quarter financial results and highlights. See financial details here:
#PlantBasedMedicines
1
5
17
Foal medicine specialist, Dr. Siobhan McAuliffe, discusses the infectious causes of diarrhea.
#FoalHealth
0
1
16
Jaguar Health today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi to Direct Relief, a Santa Barbara, California-based humanitarian aid organization.
0
5
16
For
#InternationalJaguarDay
, we take a moment to pay homage to the beautiful symbolism, cultural connection & heritage of the Jaguar. Read more from Dr. Steven King, our Chief Sustainable Supply, Ethnobotanical Research & IP Officer:
Photos: Chris Scharf
1
2
15
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
#JAGX
0
3
16
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
#JAGX
0
2
15
Jaguar Health announced updates on investigator-initiated trials of crofelemer (Mytesi®). See updates here:
#PlantBasedMedicines
0
3
16
Foal medicine specialist, Dr. Siobhan McAuliffe, examines the treatment + control of diarrhea in foals.
#FoalHealth
0
1
15
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
#crofelemer
0
4
15
Study by Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
0
3
14
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
#JAGX
0
3
14
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
#JAGX
0
3
14
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
#JAGX
0
4
14
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
#JAGX
0
4
14
Today we announced the
@FDA
invited Jaguar Health to expedite submission of regulatory filing for approval of our drug candidate to treat chemotherapy-induced diarrhea in dogs. Read more here:
#PlantBasedMedicines
2
3
12
We have submitted to the
@US_FDA
’s Center for Veterinary Medicine the last required technical section to support approval of Jaguar's oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs. Read more:
#PlantBasedMedicines
1
4
13
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
#JAGX
0
3
13
.
@napopharma
's monthly “HIV Community Conversations” series brings key advocates & activists in the HIV community together to talk about the issues that matter most to people living with & affected by HIV/AIDS. More:
#JAGX
$JAGX
0
1
11
Jaguar Health Issues Shareholder Letter: Company to Host Investor Webcast Tuesday, August 13, 2024 at 8:30 a.m. Eastern
#JAGX
0
0
12
Two Investigator-Initiated Responder Analysis Trials of Jaguar's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
#JAGX
0
2
12
Napo’s FB live series “HIV Community Conversations presented by
@napopharma
” brings key advocates and activists in the
#HIV
community together to talk about the issues that matter most to people living with and affected by HIV/AIDS.
1
3
10
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials. REMINDER: Jaguar to host investor webcast Monday, August 22nd at 8:30 a.m. Eastern regarding second quarter 2022 financials and company updates.
0
1
9
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome & Congenital Diarrheal Disorders
#JAGX
0
1
11
Jaguar to hold investor webcast January 12th at 10:30 AM EST to highlight unmet medical need of cancer therapy-related diarrhea and Jaguar's mental health Entheogen Therapeutics Initiative to discover novel therapies derived from psychoactive plants
0
0
9
Jaguar Health Reports Q4 2023 Financial Results; Investor Webcast 8:30 a.m. Eastern Today
0
0
11
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
#JAGX
0
2
11
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication
0
0
8
Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
#JAGX
#Crofelemer
0
3
9
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
#JAGX
#Crofelemer
0
0
9
$JAGX CEO Lisa Conte will be presenting at the Biotech Showcase next week in San Francisco. Learn more:
0
3
9
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates
0
0
8
Jaguar announces completion of key milestone in process of establishing Indena as an approved crofelemer manufacturer, supporting expansion of manufacturing volume required for potential additional indications for crofelemer, including CTD
0
0
9
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
0
0
8
1
0
9
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea
0
3
9
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
0
2
8
As friends of the environment and local and Indigenous communities, we stand behind the fight to protect our planet,
#IndigenousRights
and support Nemonte Nenquimo, one of
@TIME
’s 100 most influential people in the world. Read her inspiring story:
0
2
9
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
#JAGX
#Crofelemer
0
1
8
Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy. Investor Call Nov. 14th at 9 a.m. EST More:
#JAGX
$JAGX
2
1
8
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
#JAGX
0
1
9
Jaguar Health and Filament Health, with funding from One Small Planet, form joint venture Magdalena Biosciences to develop botanical pharmaceutical drug candidates for mental health illnesses
0
0
8
Napo Pharmaceuticals, a Jaguar family company, announced that a new US patent has been issued to Napo for methods for treating congenital diarrheal disorders with crofelemer, Napo's novel plant-based prescription drug.
#JAGX
0
4
9
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar’s Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
0
0
8
"Forests provide materials for food, medicine, shelter, income, and forests provide habitat for millions of species of plants, animals, birds, insects and microorganisms" ~ Ethnobotanist Dr. Steven King Learn more:
#IntlForestDay
🌲🌳🌴🌎
0
4
9
Jaguar CEO Lisa Conte was interviewed recently by Pharmaceutical Executive to discuss how a climb up Mount Kilimanjaro would spark a decades-long quest to accelerate breakthroughs in plant-based drugs and supportive care.
0
1
8
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
#JAGX
#Crofelemer
0
0
8
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
0
0
8
Jaguar is pleased to announce that Sandra M. Swain, MD, FACP, FASCO, an internationally renowned physician/scientist with 30+ years of experience, has joined our Scientific Advisory Board.
0
0
7
Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
#JAGX
0
0
8
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
0
0
7
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
#crofelemer
0
2
9
We're excited to announce that our subsidiary
@NapoPharma
launched a web-based iAssist component of the NapoCares patient support program to automate the patient prescription process for Mytesi® (Crofelemer):
#PlantBasedMedicines
0
2
7
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8, 2023 from 1:00 PM to 2:30 PM EST
0
2
8
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
#JAGX
#Crofelemer
0
1
7
We are happy to share some exciting news in the rare disease space - an independent study demonstrates the potential of our drug crofelemer to treat microvillus inclusion disease (MVID).
0
2
8
REMINDER: Jaguar to Hold Investor Webcast Thursday, Jan 12th at 10:30 AM EST to Highlight Unmet Medical Need of CTD and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
0
0
7
“We believe his broad sales, marketing, and analytical expertise in the pharmaceutical industry, and in the HIV sector at
@napopharma
, will play a significant role as we continue to focus on expanding sales of our Mytesi drug product..." More:
#JAGX
$JAGX
0
1
7
Jaguar Health today announced that on Tuesday, January 31, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Investor Select Conference.
0
0
7
Jaguar Health provides updates regarding the company’s focus on rare and orphan disease indications in the U.S. & Europe
0
0
8
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
0
1
7
Preclinical Study Results Expected to Provide Key Supportive Data for Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Targeted Cancer Therapy. More:
#JAGX
$JAGX
0
1
7
An article titled “Jaguar Health seeks pharma partner for plant-based cancer supportive care drug, CEO says” was published October 18, 2023 in Mergermarket.
#jagx
#crofelemer
0
2
8
Study data on quality of life for breast cancer patients and survivors, supported by Napo Pharmaceuticals (a Jaguar Health family company), published on San Antonio Breast Cancer Symposium (SABCS) website
#sabcs2023
0
1
8
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials. REMINDER: Jaguar to host investor webcast Monday, November 14th at 8:30 a.m. Eastern regarding third quarter 2022 financials and company updates.
0
0
6
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million. Jaguar to host investor webcast Monday, March 27th at 8:00 a.m. Eastern regarding 2022 financials and company updates.
#JAGX
#Crofelemer
0
2
7
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
#JAGX
#Crofelemer
0
0
6
Today is National Latinx AIDS Awareness Day. Visit
@HIVGov
for information about
#HIV
testing, prevention and awareness in Latinx and Hispanic communities:
#NLAAD2020
0
0
7
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions
0
2
5
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
0
0
5
Jaguar Health announces establishment of board of directors for newly formed joint venture Magdalena Biosciences
0
0
7
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
#Canalevia
0
2
6
Jaguar Health Reports Voting Results from January 20, 2023 Special Meeting of Stockholders
0
1
5
Lisa Conte, Jaguar's president, founder, and CEO, will be presenting at
#NobleCon18
at the Hard Rock / Guitar Hotel on Thursday, April 21, 2022. Admission is free for investors at any level – institutional through to self-directed novices. Register at
0
1
7
Jaguar Health Announces Time Change for March 27, 2023 Investor Webcast to 8:00 AM EDT
#JAGX
#Crofelemer
0
1
6
#JAGX
Subsidiary
@napopharma
Receives Orphan-Drug Designation for Mytesi for Treatment of Short Bowel Syndrome
0
2
7